comparemela.com

Latest Breaking News On - Serological sciences network - Page 1 : comparemela.com

U of M researchers studying how young people, immunocompromised respond to the vaccines

Study finds COVID-19 vaccines safe for IBD patients

Los Angeles (June 8, 2021) IBDs, including Crohn s disease and ulcerative colitis, are chronic conditions that occur when the intestinal immune system becomes overreactive, causing chronic diarrhea and other digestive symptoms. In a published survey at the beginning of COVID-19 vaccine distribution, 70% of IBD patients reported concern about side effects from the vaccines. What we ve learned is that if you have IBD, the side effects you re likely to experience after a vaccine are no different than they would be for anyone else, said Gil Melmed, MD, corresponding author of the study and director of Inflammatory Bowel Disease Clinical Research at Cedars-Sinai. If you re being treated with advanced therapies such as biologics, these side effects might even be milder. So, don t let that be a reason that you re not getting vaccinated.

Page A1 | E-Editions | roanoke com

Page A1 | E-Editions | roanoke com
roanoke.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from roanoke.com Daily Mail and Mail on Sunday newspapers.

NCI Deputy Director Dinah Singer, Ph D

Dinah Singer, Ph.D. NCI Deputy Director for Scientific Strategy and Development As the National Cancer Institute’s (NCI) deputy director for scientific strategy and development, Dinah Singer, Ph.D., works closely with the NCI director and other deputy directors to carry out the institute’s mission. Prior to taking on this role in 2019, she served as director of NCI’s Division of Cancer Biology (DCB), a position she held for 20 years.  As deputy director, Dr. Singer leads a number of key initiatives at NCI. In early 2020, as part of NCI’s response to the COVID-19 pandemic, she led the rapid creation of the Serological Sciences Network (SeroNet) to expand serological testing capacity and research to characterize the immune responses elicited by the SARS-CoV-2 viral infection.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.